Staying on a GLP-1 Long-Term: Maintenance, Not a Finish Line

The question every successful GLP-1 patient eventually reaches: I’ve hit my goal — now what? Stay on it forever? Taper off? Stop? It’s the most important decision in treatment, and the evidence points somewhere many people don’t expect.

What the evidence says about stopping

The studies here are unusually clear, and worth knowing before you decide:

• STEP 1 extension (semaglutide): one year after stopping, participants had regained about two-thirds of the weight they’d lost, and much of their cardiometabolic improvement reverted.
• SURMOUNT-4 (tirzepatide): people switched to placebo after the initial phase regained roughly 14% of body weight over the following year, while those who stayed on kept losing.

This isn’t a willpower gap. As covered in rebound weight gain and the set-point idea, the medication suppresses appetite biology while it’s present; remove it and hunger, food noise, and the body’s weight-defense mechanisms return — usually within weeks.

Why obesity medicine reframes it as chronic care

Because of that pattern, the field increasingly treats GLP-1 therapy the way it treats blood-pressure or cholesterol medication: managing a chronic condition, not completing a course. You wouldn’t expect blood pressure to stay down after stopping the pill that was controlling it; obesity behaves similarly. “Reaching goal weight” is the medication working, not a signal that its job is done.

That framing takes the moral weight off the decision. Needing ongoing medication to maintain a result isn’t failure — it’s how a chronic condition works.

The maintenance-dose question

Staying on doesn’t necessarily mean staying at the maximum dose. Your maintenance dose is whatever holds your result at a side-effect level you can live with — and for many people that’s a middle dose, not the top of the ladder. The Zepbound label, for instance, lists multiple doses as maintenance options. “Lowest dose that keeps the result” is a legitimate, common strategy, worked out with your prescriber and your own tracked data.

What about tapering or stopping?

Some people do stop or step down — by choice, cost, side effects, or life circumstances. If that’s you, the goal is to make the transition as controlled as possible:

• Do it with your prescriber, not abruptly on your own.
• Expect appetite to return — that’s the early-warning sign, usually before the scale moves.
• Front-load the habits that carry maintenance: protein, resistance training to protect the muscle you kept, and honest tracking.
• A dose-reduction maintenance (staying on a lower dose indefinitely) is an active, reasonable middle path for many.

The people who maintain best after any change tend to be the ones watching more than the scale — appetite, food noise, and weight trend together, so drift gets caught early instead of discovered late.

The bottom line

Reaching your goal on a GLP-1 is a milestone, not an exit. The evidence says stopping usually means regaining, and obesity medicine increasingly plans for long-term maintenance — often at a lower dose — rather than a finish line. Whatever you and your prescriber decide, decide it with your data in hand, because a documented baseline of what your maintenance looks like is exactly what makes the next call a good one.

Sources: STEP 1 extension (Wilding et al., Diabetes Obes Metab 2022); SURMOUNT-4 (Aronne et al., JAMA 2024); Zepbound prescribing information (maintenance dosing).